GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NanoVibronix Inc (NAS:NAOV) » Definitions » Cyclically Adjusted Price-to-FCF

NanoVibronix (NanoVibronix) Cyclically Adjusted Price-to-FCF : (As of Apr. 30, 2024)


View and export this data going back to 2015. Start your Free Trial

What is NanoVibronix Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


NanoVibronix Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for NanoVibronix's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NanoVibronix Cyclically Adjusted Price-to-FCF Chart

NanoVibronix Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

NanoVibronix Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of NanoVibronix's Cyclically Adjusted Price-to-FCF

For the Medical Devices subindustry, NanoVibronix's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NanoVibronix's Cyclically Adjusted Price-to-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NanoVibronix's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where NanoVibronix's Cyclically Adjusted Price-to-FCF falls into.



NanoVibronix Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

NanoVibronix's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, NanoVibronix's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.25/129.4194*129.4194
=-0.250

Current CPI (Dec. 2023) = 129.4194.

NanoVibronix Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201403 -1.198 99.695 -1.555
201406 -1.748 100.560 -2.250
201409 -2.038 100.428 -2.626
201412 -1.885 99.070 -2.462
201503 -2.282 99.621 -2.965
201506 -2.545 100.684 -3.271
201509 -1.158 100.392 -1.493
201512 -1.659 99.792 -2.152
201603 -1.611 100.470 -2.075
201606 -2.092 101.688 -2.663
201609 -1.166 101.861 -1.481
201612 -1.860 101.863 -2.363
201703 -1.769 102.862 -2.226
201706 -2.235 103.349 -2.799
201709 -2.109 104.136 -2.621
201712 -2.557 104.011 -3.182
201803 -2.707 105.290 -3.327
201806 -3.140 106.317 -3.822
201809 -2.484 106.507 -3.018
201812 -2.711 105.998 -3.310
201903 -2.814 107.251 -3.396
201906 -2.336 108.070 -2.797
201909 -3.153 108.329 -3.767
201912 -3.185 108.420 -3.802
202003 -2.466 108.902 -2.931
202006 -1.331 108.767 -1.584
202009 -1.488 109.815 -1.754
202012 -1.241 109.897 -1.461
202103 -0.791 111.754 -0.916
202106 -1.546 114.631 -1.745
202109 -0.487 115.734 -0.545
202112 -0.674 117.630 -0.742
202203 -1.244 121.301 -1.327
202206 -1.428 125.017 -1.478
202209 -1.403 125.227 -1.450
202212 -0.900 125.222 -0.930
202303 -0.727 127.348 -0.739
202306 -0.739 128.729 -0.743
202309 -0.396 129.860 -0.395
202312 -0.250 129.419 -0.250

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


NanoVibronix  (NAS:NAOV) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


NanoVibronix Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of NanoVibronix's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


NanoVibronix (NanoVibronix) Business Description

Traded in Other Exchanges
Address
525 Executive Boulevard, Elmsford, New York, NY, USA, 10523
NanoVibronix Inc manufactures noninvasive biological response-activating devices that target biofilm prevention, pain therapy, and wound healing and can be administered at home, without the assistance of medical professionals. Its primary products are UroShield; PainShield; and WoundShield. Each of its UroShield, PainShield, and WoundShield products employs a small, disposable transducer that transmits low frequency, low intensity ultrasound acoustic waves that seek to repair and regenerate tissue, musculoskeletal and vascular structures, and decrease biofilm formation on urinary catheters and associated urinary tract infections. The company derives revenues from selling its products directly to patients as well as through distributor agreements.
Executives
Christopher M Fashek director 8023 VANTAGE DR, SAN ANTONIO TX 78230
Stephen Russell Brown officer: Chief Financial Officer 18-B NEIL COURT, OCEANSIDE NY 11572
Aurora Cassirer director C/O NANOVIBRONIX, INC.,, 525 EXECUTIVE BOULEVARD, ELMSFORD NY 10523
Maria Schroeder director C/O NANOVIBRONIX, INC.,, 525 EXECUTIVE BOULEVARD, ELMSFORD NY 10523
Brian M Murphy director, officer: Chief Executive Officer 525 EXECUTIVE BOULEVARD, ELMSFORD NY 10523
Michael Ferguson director 525 EXECUTIVE BOULEVARD, ELMSFORD NY 10523
Thomas Mika director TEGAL CORP, 2201 SOUTH MCDOWELL BLVD, PETALUMA CA 94954
Ira A Greenstein director IDT CORP, 520 BROAD STREET, NEWARK NJ 07102
Harold Jacob director, officer: Chief Medical Officer HAADMUR MEBUYON 26, HARNOT, JERUSALEM L3 95403
Martin M Goldstein director C/O NANOVIBRONIX, INC., 525 EXECUTIVE BOULEVARD, ELMSFORD NY 10523
William Stern director, officer: Chief Executive Officer 525 EXECUTIVE BOULEVARD, ELMSFORD NY 10523
Jona Zumeris director, officer: VP of Technology 105 MAXESS ROAD, SUITE S124, MELVILLE NY 11747
Miriam W Kelly 10 percent owner P.O. BOX 1443, BROOKLANDVILLE MD 21022